The new 250-page BioWorld Top 25 Biotechnology Drugs Report delivers a comprehensive and in-depth analysis of the top 25 biotech drugs. Detailed drug profiles, analysis, tables, and charts are provided. This is the perfect resource for analysts, investors, and biotech/pharma executives in need of drug sales data and trends. View sample here.

Company Product Description Indication Status (Date) Jazz Pharmaceuticals Inc. JZP-8 An intranasal spray formulation incorporating clonazepam Recurrent acute repetitive seizures Received orphan drug designation (1/7) MAP Pharmaceuticals MAP0004 An inhaled version of dihydroergotamine Migraine Reached an SPA agreement with the FDA on two Phase III trials (1/16) YM Biosciences Inc. AeroLEF An inhaled-delivery composition of free and liposome-encapsulated fentanyl Acute pain FDA

Company Product Description Indication Status (Date) Ovation Pharmaceuticals Inc. Clobazam Lennox-Gastaut syndrome Adjunctive treatment; a 1,5 benzodiazepine with anticonvulsant properties Granted orphan drug designation (1/4) TAP TAK-390MR A proton pump inhibitor Erosive esophagitis Pharmaceutical and nonerosive reflux Products Inc. disease Submitted an NDA (1/4) Ocera Therapeutics Inc. AST-120 An oral agent known to adsorb bile acids and bacterial toxins and to mediate

Company Product Description Indication Status (Date) Tibotec Therapeutics Intelence Etravirine tablets; a non-nucleoside reverse transcriptase inhibitor HIV infection FDA approved Intelence for HIV patients who have failed treatment with other antiretrovirals (1/22) Vertex Pharmaceuticals Inc. Telaprevir Protease inhibitor Treatment-naive hepatitis C virus FDA requested an additional 48-week Phase III trial before the company can submit a regulatory filing (1/23) MiddleBrook

Company Product Description Indication Status (Date) Depomed Inc. Glumetza (FDA approved) Metformin hydrochloride extended-release tablets Type II diabetes Received approval from the FDA for the 1,000-mg tablet (1/2) Takeda Pharmaceutical Co. Ltd. Alogliptin An oral, once-daily selective dipeptidyl peptidase-4 inhibitor Type II diabetes Submitted an NDA (1/4); The NDA was accepted for review by the FDA (2/29) NOTES: BLA = Biologics license application CMA = Continuous marketing

Company Product Description Indication Status (Date) SkyePharma plc and ScielePharma Inc. Sular A calcium channel blocking agent that uses the Geo-Matrix technology High blood pressure Approved all four new dosage strengths (1/3) ZymoGenetics Inc. Recothrom Recombinant, plasma-free thrombin made from Chinese hamster ovary cells For use during surgery to control minor bleeding FDA approved it for use as a topical hemostat (1/17) Abbott Simcor A fixed-dose combination of Niaspan

Company Product Description Indication Status (Date) MGI Pharma Inc. and Helsinn Healthcare SA Aloxi (FDA-approved) Palonosetron hydrochloride Nausea and vomiting associated with chemotherapy Accepted the sNDA for oral capsules (1/3) TransMolecular Inc. TM601 Nonradiolabeled version Malignant glioma Granted orphan drug designation (1/7) Vion Pharmaceuticals Inc. VNP40101M Cloretazine Relapsed acute myelogenous leukemia FDA lifted a clinical hold on the Phase III trial

High-income countries Deaths in millions % of deaths Coronary heart disease 1.34 17.1 Stroke and other cerebrovascular diseases 0.77 9.8 Trachea, bronchus, lung cancers 0.46 5.8 Lower respiratory infections 0.34 4.3 Chronic obstructive pulmonary disease 0.3 3.9 Colon and rectum cancers 0.26 3.3 Alzheimer’s and other dementias 0.22 2.7 Diabetes mellitus 0.22 2.7 Breast cancer 0.15 1.9 Stomach cancer 0.14 1.8 Middle-income countries Deaths in millions % of

Amgen Inc. $14,771M Genentech Inc. $11,724M Gilead Sciences Inc. $4,230M Genzyme Corp. $3,814M Biogen Idec Inc. $3,172M Cephalon Inc. $1,773M Celgene Corp. $1,406M ImClone Systems Inc. $591M Affymetrix Inc. $371M PDL BioPharma Inc. $259M Albany Molecular Research Inc. $193M QLT Inc. $128M AEterna Zentaris Inc. $42M SOURCE: BioScan: The Worldwide Biotech Industry Reporting Service.

Company Product Description Indication Status (Date) DOR BioPharma Inc. BDP Beclomethasone dipropionate Pediatric Crohn’s disease Granted orphan drug designation (1/3) Biogen Idec and Elan Corp. plc Tysabri Natalizumab Crohn’s disease FDA approved Tysabri for moderate to severe Crohn’s disease (1/14) ZymoGenetics Atacicept Inc. and Merck Serono Antagonist protein that binds to the TNF cytokines BLyS and APRIL Systemic lupus erythematosus Received an SPA for a Phase II/III

Thermo Fisher Scientific Inc. $9,746M Applied Biosystems Group $2,093M Sigma-Aldrich Corp. $2,039M bioMerieux SA $1,691M Millipore Corp. $1,53M Pharmaceutical Product Development Inc. $1,414M Invitrogen Corp. $1,282M Idexx Laboratories Inc. $923M Qiagen NV $650M Bruker Corp. $548M Gen-Probe Inc. $403M Affymetrix Inc. $371M SOURCE: BioScan: The Worldwide Biotech Industry Reporting Service.

Public/Other Private Biotechs Public Offerings 2000 10.09 3.94 23.64 2001 6.12 3.75 4.49 2002 5.33 3.23 1.39 2003 9.46 3.33 3.63 2004 10.46 4.89 5.46 2005 9.73 4.81 5.58 2006 8.53 5.13 6.63 2007 13.42 6.23 5.13 SOURCE: BioWorld Financial Watch.

Drug name (maker) 2007 2006 2005 2004 2003 1 Rituxan (Genentech) $5,467M $3,881M $1,831M $1,574M $1,489M 2 Enbrel (Amgen) $5,275M $4,379M $3,673M $1,900M (Amgen only) $1,300M (Amgen only) 3 Herceptin (Genentech) $4,809M $3,150M $2,416M $1,591M $2,064M 4 Avastin (Genentech) $4,070M $2,380M $1,133M (U.S.) $545M (U.S.) $-- 5 Aranesp (Amgen) $3,614M $4,121M $3,273M $2,500M $1,600M 6 Remicade (J&J) $3,327M $3,014M $2,535M $2,145M $1,729M 7 Lantus

Amgen Inc. 17,500 Sepracor Inc. 2,277 Mylan Inc. 12,000 Alpharma Inc. 2,000 Genentech Inc. 11,174 Amylin Pharmaceuticals Inc. 1,900 Pharmaceutical Product Development Inc. 10,200 Biovail Corp. 1,734 Genzyme Corp . 10,000 . Celgene Corp 1,685 Barr Pharmaceuticals Inc. 8,900 Actelion Ltd. 1,252 Covance Inc. 8,700 Albany Molecular Research Inc. 1,226 CSL Ltd. 8,423 Endo Pharmaceuticals 1,208 Allergan Inc. 7,886 Vertex Pharmaceuticals 1,132 PAREXEL International

(in millions of U.S. dollars) Public offerings Private biotechs Public other Total Jan. 573.5 518.7 230.1 1,322.3 Feb. 655.4 763.5 1,334.3 2,753.2 March 174.1 798.7 865.1 1,837.8 April 559.1 513.7 901.3 1,974.1 May 1,257.5 517.1 4,684.0 6,458.6 June 568.7 447.2 1,956.8 2,972.7 July 213.5 430.1 370.6 1,014.2 Aug. 42.2 478.4 530.0 1,050.7 Sept. 225.0 499.1 207.9 931.9 Oct. 464.5 462.6 709.2 1,636.3 Nov. 293.0 398.3 880.3 1,571.6 Dec

(in billions of rounded U.S. dollars)

Company Product/Description/Indication Status (Date) 4SC AG SC12267, new type of small-molecular active agent from the class of disease-modifying anti-rheumatic drugs; works as a selective inhibitor in the biosynthesis of pyrimidine for rheumatoid arthritis Phase IIa data showed it was safe and well tolerated (11/07) Active Biotech AB and Chelsea Therapeutics International Ltd. ABR-224050, oral inhibitor of dihydroorotate dehydrogenase for rheumatoid arthritis Completed microdosing study